Your Path to Personalized Weight Loss: Understanding What Are the Mounjaro Doses

Last reviewed: July 17, 2026

Last updated: July 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide, the active ingredient in Mounjaro, works by activating two hormone pathways that control appetite and blood sugar—the GLP-1 and GIP receptors. Understanding how tirzepatide doses are structured helps you anticipate your treatment journey and set realistic expectations for weight loss. PlexusDx prescribes compounded tirzepatide injections from licensed 503A pharmacies, offering personalized dosing without the complexity of rising costs.

How Tirzepatide Dosing Works: The Step-Up Protocol

Tirzepatide therapy follows a gradual dose escalation schedule designed to minimize side effects while allowing your metabolism to adapt. Most treatment plans begin at 2.5 mg weekly, then advance by 2.5 mg increments every four weeks until reaching your therapeutic dose. This stepped approach reduces nausea, constipation, and other gastrointestinal effects that can occur when the body is first exposed to GLP-1 and GIP signaling.

The typical dose range spans from 2.5 mg to 15 mg weekly, with many patients achieving optimal weight loss results between 5 mg and 10 mg doses. Your healthcare provider determines your target dose based on your initial response, weight loss goals, and tolerance to the medication. PlexusDx ensures that your dose may increase as you progress—but your monthly price stays flat at $289 per month, removing financial barriers to reaching your ideal dose.

Why Doses Increase Over Time: Building Metabolic Adaptation

Your body naturally develops tolerance to GLP-1 and GIP receptor stimulation over weeks of consistent therapy. Starting at lower doses gives your digestive system time to adjust to increased fullness signals and slower gastric emptying. As your body adapts, incrementally higher doses reactivate the appetite-suppressing and blood-sugar-regulating effects that drive weight loss.

Research shows that the greatest weight loss occurs when patients reach their maintenance dose and sustain therapy for at least 16 weeks. Patients who skip doses or advance too quickly often experience stronger side effects without proportional weight loss benefits. PlexusDx supports your dose progression with ongoing clinical guidance, ensuring you advance safely and see measurable results at every tier.

Starting Dose vs. Maintenance Dose: What to Expect

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Mounjaro or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Maintenance doses—usually 5 mg, 10 mg, or 15 mg weekly—represent the dose level where you experience consistent weight loss and metabolic benefits. Most patients reach their maintenance dose within 8 to 12 weeks of starting therapy. PlexusDx coordinates with compounding pharmacies to ensure your injections are prepared at your exact therapeutic dose each month, with pricing that never changes regardless of whether you're at 2.5 mg or 15 mg.

Personalizing Your Tirzepatide Dose with Genetic Insights

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

The Precision Peptide test also examines FTO rs9939609 and MC4R rs17782313 variants, which regulate energy expenditure and metabolic set point. Patients with specific genetic profiles may experience faster weight loss at lower doses, while others require higher maintenance doses for optimal results. Understanding your genetic predispositions transforms tirzepatide therapy from one-size-fits-all treatment into truly personalized medicine aligned with your biology.

Tirzepatide Dosing vs. Semaglutide: Key Differences

While both tirzepatide and semaglutide are GLP-1 based therapies, tirzepatide's addition of GIP receptor activation creates a dual-mechanism approach that often produces faster and more substantial weight loss. Tirzepatide doses typically range from 2.5 to 15 mg weekly, whereas semaglutide doses range from 0.25 to 2.4 mg weekly—meaning the nominal dose numbers differ, but both follow the same gradual escalation principle. Clinical trials show tirzepatide produces approximately 15–22% weight loss at maintenance doses, compared to semaglutide's 10–17% range, though individual results vary widely.

PlexusDx offers both compounded semaglutide (at $189/mo month-to-month, or from $149/mo on the 6-month plan) and tirzepatide (at $289/mo month-to-month, or from $249/mo on the 6-month plan), allowing your provider to select the compound best matched to your genetic profile and clinical history. Some patients with specific GLP1R variants may respond exceptionally well to semaglutide, while others with favorable GIPR expression benefit more from tirzepatide's dual-pathway activation. Your Precision Peptide Genetic Test results guide this selection, ensuring you receive the compound optimized for your unique peptide biology.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What is a typical starting dose for tirzepatide, and when do I increase it?

Most patients begin tirzepatide at 2.5 mg injected once weekly. After two to four weeks, your provider increases the dose by 2.5 mg increments—moving to 5 mg, then 7.5 mg, and so on—until reaching your target maintenance dose. PlexusDx coordinates this advancement with your prescribing provider, ensuring each monthly supply matches your current dose level at the same flat $289/mo price.

Is there clinical evidence that tirzepatide doses above 10 mg produce better weight loss results?

Clinical trials show that tirzepatide weight loss continues to improve through 15 mg doses, though the incremental benefit between 10 mg and 15 mg is smaller than the jump from 5 mg to 10 mg. Most patients achieve satisfactory weight loss (15–20% body weight reduction) between 5 mg and 10 mg maintenance doses. Your provider may recommend advancing beyond 10 mg if you plateau or have specific metabolic needs, and PlexusDx keeps your price unchanged regardless of dose.

What if I need to stay at a lower tirzepatide dose due to side effects?

Remaining at a lower dose (2.5 mg, 5 mg, or 7.5 mg) is a valid long-term strategy if you're experiencing meaningful weight loss and side effects remain manageable. Some patients achieve their weight loss goals at 5 mg and choose to stay there; others need to advance to 10 mg or higher. PlexusDx supports either path without cost penalty, so your choice is driven by your results and comfort, not financial pressure to move up.

Does PlexusDx charge differently based on my tirzepatide dose level?

No. PlexusDx charges a flat $289/mo for compounded tirzepatide injections, regardless of whether you're taking 2.5 mg or 15 mg weekly. This pricing model removes the financial incentive to under-dose or hesitation about advancing to your optimal therapeutic dose. Your dose may need to go up. Your price won't.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

The Precision Peptide Genetic Test analyzes 14 metabolic pathways and 49 peptides, including GIPR, FTO, and MC4R variants that influence how strongly you respond to GLP-1 and GIP signaling. Patients with favorable GIPR expression often experience robust weight loss at standard doses, while others may require higher doses or respond better to semaglutide alone. This $99 add-on test, taken after your first month of treatment, personalizes your dose trajectory and compound selection.

Related Reading

• Mounjaro For Weight Loss 2
• Weight Loss Mounjaro
• Mounjaro Weight Loss By Week
• Weight Loss Injections Mounjaro

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.